HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W
Cancer Discov. 2012 2 (10): 922-33

PMID: 22956644 · PMCID: PMC3473100 · DOI:10.1158/2159-8290.CD-12-0108

MeSH Terms (26)

Adenocarcinoma Adenocarcinoma of Lung Afatinib Animals Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents Cell Line, Tumor Cetuximab Class I Phosphatidylinositol 3-Kinases Drug Resistance, Neoplasm ErbB Receptors Erlotinib Hydrochloride Humans Lung Neoplasms Mice Mice, Nude Molecular Targeted Therapy Mutation Phosphatidylinositol 3-Kinases Phosphorylation Protein Kinase Inhibitors Quinazolines Receptor, ErbB-2 RNA, Small Interfering RNA Interference

Connections (2)

This publication is referenced by other Labnodes entities: